´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 2) : 2022-03-31±³À°ÀÏÀÚ : 2022-03-31
±³À°Àå¼Ò : (¿Â, ¿ÀÇÁ¶óÀÎ º´Çà) ¿ÀÇÁ¶óÀÎ Àå¼Ò: ¼¿ï ÄÚ¿¢½º
±³À°ÁÖÁ¦ :
(¿Â-¿ÀÇÁº´Çà) APASL 2022 (DAY 2)ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : APASL 2022 Áغñ»ç¹«±¹
¿¬¶ôó : 02-707-0091
À̸ÞÀÏ :
apasl2022@insession.co.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 25 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 800,000¿ø
ºñ°í Category Early Bird Rate Regular Rate Onsite Rate December 31(Fri), 2021 February 20(Sun), 2022 Off-line Virtual Off-line Virtual Off-line VirtualAPASL Member USD 300 USD200 USD400 USD300 USD 500 USD 400Non APASL Member USD 500 USD 300 USD 600 USD 400 USD 700 USD 500Trainee/Resident/Nurse USD 200 USD 100 USD 300 USD 200 USD 400 USD 300Accompanying Person USD 150 - USD 200 - USD 300 -Industry Partner USD 600 USD 600 USD 700 USD 700 USD 800 USD 800 / *»çÀüµî·Ï2022³â 2¿ù 20ÀÏ(ÀÏ)±îÁö [ÇöÀå] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 15¸¸¿ø, µ¿¹ÝÀÚ 15¸¸¿ø, Industry Partner 70¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 25¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 12¸¸¿ø, Industry Partner 70¸¸¿ø, *ÇöÀåµî·Ï [ÇöÀå] Àü¹®ÀÇ 35¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 18¸¸¿ø, µ¿¹ÝÀÚ 18¸¸¿ø, Industry Partner 80¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ/Àü°øÀÇ/°£È£»ç 15¸¸¿ø, Industry Partner 80¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-31 101+102, 1F 10:30~10:50 Expanding treatment indications for CHB Young-Suk Lim(University of Ulsan College of Medicine)
±³À°½Ã°£ 03-31 101+102, 1F 10:50~11:10 Finite treatment of CHB with current antivirals: Is it possible? Chun-Jen Liu(National Taiwan University College of Medicine and Hospital)
±³À°½Ã°£ 03-31 101+102, 1F 11:10~11:30 Current and promising surrogates to guide HBV therapy Yasuhito Tanaka(Faculty of Life Sciences, Kumamoto University)
±³À°½Ã°£ 03-31 101+102, 1F 11:30~11:50 Future perspectives in HBV management Henry LY Chan(Faculty of Medicine, The Chinese University of Hong Kong)
Åä·Ð 03-31 101+102, 1F 11:50~12:00 Discussion ()
±³À°½Ã°£ 03-31 101+102, 1F 13:30~13:50 Hepatocarcinogenesis in HBV-related HCC Nobuyuki Enomoto(University of Yamanashi Faculty of Medicine)
±³À°½Ã°£ 03-31 101+102, 1F 13:50~14:10 HCC risk stratification in CHB patients treated with antivirals Tai-Chung Tseng(National Taiwan University Hospital)
±³À°½Ã°£ 03-31 101+102, 1F 14:10~14:30 Prevention of HBV-related HCC through antiviral treatment Jinlin Hou(Nanfang Hospital, Southern Medical University)
±³À°½Ã°£ 03-31 101+102, 1F 14:30~14:50 Prevention of HBV-related HCC beyond antiviral treatment Jeong-Hoon Lee(Seoul National University College of Medicine)
Åä·Ð 03-31 101+102, 1F 14:50~15:00 Discussion ()
±³À°½Ã°£ 03-31 101+102, 1F 16:00~16:20 HBV cccDNA: A hurdle for a cure Patrick Kennedy(Barts and The London School of Medicine & Dentistry)
±³À°½Ã°£ 03-31 101+102, 1F 16:20~16:40 CRISPR/Cas9: targeting cccDNA and integrated HBV Kyun-Hwan Kim(Sungkyunkwan University School of Medicine)
±³À°½Ã°£ 03-31 101+102, 1F 16:40~17:00 Immunological cure of HBV infection Qin Ning(Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology)
±³À°½Ã°£ 03-31 101+102, 1F 17:00~17:20 Current and emerging therapeutics for HBV cure Man Fung Yuen(The University of Hong Kong)
Åä·Ð 03-31 101+102, 1F 17:20~17:30 Discussion ()
±³À°½Ã°£ 03-31 201+202, 2F 10:30~10:50 Pathogenic role of gut dysbiosis in ALD and NAFLD GwangPyo Ko(Graduate School of Public Health, Seoul National University)
±³À°½Ã°£ 03-31 201+202, 2F 10:50~11:10 Gut microbiome-based personalized medicine in NAFLD Rohit Loomba(University of California at San Diego)
±³À°½Ã°£ 03-31 201+202, 2F 11:10~11:30 Alterations of gut microbiome in cirrhosis and its complications Jasmohan S. Bajaj(Virginia Commonwealth University School of Medicine)
±³À°½Ã°£ 03-31 201+202, 2F 11:30~11:50 Therapeutic role of FMT in chronic liver diseases SM Shasthry(Institute of Liver and Biliary Sciences)
Åä·Ð 03-31 201+202, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 03-31 201+202, 2F 13:30~13:50 Updates on pathogenesis of ALD Kenichi Ikejima(Juntendo University School of Medicine)
±³À°½Ã°£ 03-31 201+202, 2F 13:50~14:10 Noninvasive diagnostic biomarkers in ALD Suthat Liangpunsakul(Indiana University School of Medicine)
±³À°½Ã°£ 03-31 201+202, 2F 14:10~14:30 Upcoming pharmacological treatment in ALD Gyongyi Szabo(Harvard Medical School)
±³À°½Ã°£ 03-31 201+202, 2F 14:30~14:50 Liver trasnplantation in ALD Dong Jin Joo(Yonsei University College of Medicine)
Åä·Ð 03-31 201+202, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 03-31 201+202, 2F 16:00~16:20 Viral hepatitis Ji Hoon Kim(Korea University College of Medicine)
±³À°½Ã°£ 03-31 201+202, 2F 16:20~16:40 NAFLD and ALD Rosmawati Mohamed(Faculty of Medicine, University of Malaya)
±³À°½Ã°£ 03-31 201+202, 2F 16:40~17:00 Cirrhosis Cosmas Rinaldi Lesmana(Dr. Cipto Mangunkusumo National General Hospital)
±³À°½Ã°£ 03-31 201+202, 2F 17:00~17:20 Liver cancer Kang Mo Kim(University of Ulsan College of Medicine)
Åä·Ð 03-31 201+202, 2F 17:20~17:30 Discussion ()
±³À°½Ã°£ 03-31 203, 2F 10:30~10:50 HCV elimination: Korean expriences Do Young Kim(Yonsei University College of Medicine)
±³À°½Ã°£ 03-31 203, 2F 10:50~11:10 HCV elimination: Turkey experiences A.Kadir Dokmeci(Ankara University School of Medicine)
±³À°½Ã°£ 03-31 203, 2F 11:10~11:30 Global strategies for HCV microelimination Lai Wei(Tsinghua University School of Clinical Medicine)
±³À°½Ã°£ 03-31 203, 2F 11:30~11:50 APASL strategies for HCV elimination in Asia-Pacific Region Saeed Sadiq Hamid(Aga Khan University and Hospital)
Åä·Ð 03-31 203, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 03-31 203, 2F 13:30~13:50 Impact of DAA therapy in advanced/decompensated cirrhosis Alexander Thompson(St. Vincent¡¯s Hospital Melbourne)
±³À°½Ã°£ 03-31 203, 2F 13:50~14:10 When is optimal time for DAA therapy in patients with HCC? Ming-Lung Yu(Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung)
±³À°½Ã°£ 03-31 203, 2F 14:10~14:30 Does DAA therapy increase survival in patients with HCV-related HCC? Yock Young Dan(National Univeristy Hospital)
±³À°½Ã°£ 03-31 203, 2F 14:30~14:50 Mangement of HCV patients after achieving SVR by DAA therapy Jung Hyun Kwon(College of Medicine, The Catholic University of Korea)
Åä·Ð 03-31 203, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 03-31 205A, 2F 08:00~08:20 Scientific strategy to cure hepatitis B Peter Revill(Royal Melbourne Hospital)
±³À°½Ã°£ 03-31 205A, 2F 08:20~08:40 Hot topics in basic science for HBV elimination Pei-Jer Chen(National Taiwan University Hospital)
Åä·Ð 03-31 205A, 2F 08:40~09:00 Discussion ()
±³À°½Ã°£ 03-31 205B, 2F 08:00~08:20 HBeAg-Positive ¡°Gray Zone¡± Phase Hyung Joon Yim(Korea University College of Medicine)
±³À°½Ã°£ 03-31 205B, 2F 08:20~08:40 HBeAg-Negative ¡°Gray Zone¡± Phase Yi-Hsiang Huang(Taipei Veterans General Hospital)
Åä·Ð 03-31 205B, 2F 08:40~09:00 Discussion ()
±³À°½Ã°£ 03-31 209A, 2F 08:00~08:20 Managment of viremic HCV-related decompensated cirrhosis Chia-Yen Dai(Kaohsiung Medical University Hospital)
±³À°½Ã°£ 03-31 209A, 2F 08:20~08:40 Management of viremic HCV-related HCC Soo Young Park(Kyungpook National University College of Medicine)
Åä·Ð 03-31 209A, 2F 08:40~09:00 Discussion ()
±³À°½Ã°£ 03-31 209A, 2F 08:00~08:20 Lille score-based, steroid non-responder with alcoholic hepatitis: G-CSF Young Kul Jung(Korea University College of Medicine)
±³À°½Ã°£ 03-31 209A, 2F 08:20~08:40 Lille score-based, steroid non-responder with alcoholic hepatitis: FMT Ki Tae Suk(Hallym University College of Medicine)
Åä·Ð 03-31 209A, 2F 08:40~09:00 Discussion ()
±³À°½Ã°£ 03-31 209AB, 2F 10:30~10:50 Malnutrition and fraility in cirrhosis Puneeta Tandon(University of Alberta)
±³À°½Ã°£ 03-31 209AB, 2F 10:50~11:10 Sleep disturbance and depression in cirrhosis Jeong-Ju Yoo(Soonchunhyang University College of Medicine)
±³À°½Ã°£ 03-31 209AB, 2F 11:10~11:30 Optimal management of hepatogenous diabetes Ming Chih Hou(Taipei Veterans General Hospital)
±³À°½Ã°£ 03-31 209AB, 2F 11:30~11:50 Hormonal and erectile dysfunction in cirrhosis Won Hyeok Choe(Konkuk University School of Medicine)
Åä·Ð 03-31 209AB, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 03-31 209AB, 2F 13:30~13:50 Updates on epidemiology of PBC and autoimmune liver diseases Kyung-Ah Kim(Inje University College of Medicine)
±³À°½Ã°£ 03-31 209AB, 2F 13:50~14:10 Advances in diagnosis of PBC and autoimmune liver diseases Gideon M Hirschfield(University of Toronto)
±³À°½Ã°£ 03-31 209AB, 2F 14:10~14:30 Current and emerging treatments for PBC and autoimmune liver diseases Ja Kyung Kim(Yonsei University College of Medicine)
±³À°½Ã°£ 03-31 209AB, 2F 14:30~14:50 Management of PBC and autoimmune diseases refractory to immunosuppressive regimens Atsushi Tanaka(Teikyo University School of Medicine)
Åä·Ð 03-31 209AB, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 03-31 209AB, 2F 16:00~16:20 Definition of ALD spectrum nomenclatures and trial endpoints Eileen L. Yoon(Hanyang University College of Medicine)
±³À°½Ã°£ 03-31 209AB, 2F 16:20~16:40 Controversies in clinical trials for alcoholic hepatitis Suthat Liangpunsakul(Indiana University School of Medicine)
±³À°½Ã°£ 03-31 209AB, 2F 16:40~17:00 Past pivotal clinical trials in alcoholic hepatitis treatment Jae-Youn Cheong(Ajou University School of Medicine)
±³À°½Ã°£ 03-31 209AB, 2F 17:00~17:20 NIAAA consortium for alcoholic hepatitis clinical trials Puneet Puri(Virginia Commonwealth University and McGuire VA Medical Center)
Åä·Ð 03-31 209AB, 2F 17:20~17:30 Discussion ()
±³À°½Ã°£ 03-31 Auditorium, 3F 09:00~09:15 Single-cell RNA sequencing in HCC Zemin Zhang(School of Life Sciences, Peking University)
±³À°½Ã°£ 03-31 Auditorium, 3F 09:15~09:30 Spectrum of Wnt/¥â-catenin oncogenic "drivers" in serially occurring HCC nodules; Needs of tumorized therapy Masao Omata(Yamanashi Central and Kita Hospitals, The University of Tokyo)
±³À°½Ã°£ 03-31 Auditorium, 3F 09:30~09:45 Sensitive and accurate viral integration detection in HBV-associated hepatocellular carcinoma Xueying Lyu(Department of Pathology, The University of Hong Kong)
±³À°½Ã°£ 03-31 Auditorium, 3F 09:45~10:00 Validation of a new HBV cure strategy in HBV infected uPA/SCID chimeric mice Yong-Yuan Zhang(HBVtech)
±³À°½Ã°£ 03-31 Auditorium, 3F 10:30~10:50 Okuda-Omata Distinguished Award TBD()
±³À°½Ã°£ 03-31 Auditorium, 3F 10:50~11:10 Powell-Sarin Lifetime Achievement Award TBD()
±³À°½Ã°£ 03-31 Auditorium, 3F 11:10~11:30 Sollano-Lesmana Great Mentor Award TBD()
±³À°½Ã°£ 03-31 Auditorium, 3F 11:40~12:00 Rising Star Award Session - Presenter 1 TBD()
±³À°½Ã°£ 03-31 Auditorium, 3F 13:30~14:00 From NAFLD to NASH and HCC: Current concepts and future perspectives Jin Mo Yang(College of Medicine, The Catholic University of Korea)
±³À°½Ã°£ 03-31 Auditorium, 3F 14:00~14:30 Acute kidney injury and hepatorenal syndrome Paolo Angeli(University-Teaching Hospital of Padova)
±³À°½Ã°£ 03-31 Auditorium, 3F 14:30~15:00 Regenerative medicine in decompensated cirrhosis Soon Koo Baik(Yonsei University Wonju College of Medicine)
±³À°½Ã°£ 03-31 Auditorium, 3F 16:00~16:20 Difference in characteristics of NALFD between Eastern and Western countries Ming-Hua Zheng(The First Affiliated Hospital of Wenzhou Medical University)
±³À°½Ã°£ 03-31 Auditorium, 3F 16:20~16:40 Recent updates of clinical trials on NASH Mary E. Rinella(Northwestern University Feinberg School of Medicine)
±³À°½Ã°£ 03-31 Auditorium, 3F 16:40~17:00 NAFLD-Associated HCC: Pathogenesis, clinical characteristics, and outcome Dae Won Jun(Hanyang University College of Medicine)
±³À°½Ã°£ 03-31 Auditorium, 3F 17:00~17:20 Liver transplantation with steatotic donor livers – the science behind their outcomes Laurie D. De Leve(Keck School of Medicine, USC)
Åä·Ð 03-31 Auditorium, 3F 17:20~17:30 Discussion ()